

NNDSS Modernization Initiative Technical Assistance Coordination Team Update

March 27, 2015

Colleagues,

Please find below the National Notifiable Diseases Surveillance System (NNDSS) Modernization Initiative (NMI) Technical Assistance (TA) Coordination Team Update for March 27, 2015. These e-mail updates are a collaboration among the Centers for Disease Control and Prevention (CDC), Council of State and Territorial Epidemiologists (CSTE), and the Association of Public Health Laboratories (APHL) and will be sent biweekly in an effort to keep reporting jurisdictions and other partners and stakeholders updated on the progress of NMI.

For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.

Message Mapping Guide Development Updates

- The “Methods for Conveying Unknown or Missing Values in Case Notification Messages” document has received final CDC approval and is expected to be posted on the [Draft MMG Web site](#) in April 2015.
- **Message Mapping Guide (MMG) Status Updates:**
 - **Mumps and Pertussis MMGs ([Stage I—Draft Phase](#)):**
 - The MMG Development Team has revised the expected posting date for the revised Mumps and Pertussis MMGs to April 2015 for a second external review period of approximately 4 weeks.
 - **Congenital Syphilis and STD MMGs ([Stage II—Reconciled Draft Phase](#))**
 - The team revised the STD MMG in response to changes suggested by the National Electronic Disease Surveillance System Base System (NBS) Team and the Message Validation, Processing, and Provisioning System (MVPS) developer AgileX.
 - The MMG Development Team delivered an updated MMG to the MVPS Team on 3/20/2015.
 - The team also delivered updated test scenarios to the MVPS Team on 3/23/2015 and expects to deliver updated test messages this week.
 - The MMG Development Team will revise the Congenital Syphilis MMG in response to the changes suggested by the NBS Team and AgileX at a later date.
 - The MMG Development Team will post the STD and Congenital Syphilis MMGs as soon as possible as [Stage III—Pilot Test-ready Draft Phase](#) versions of the MMGs, along with their artifacts.
 - **Generic v2 and Hepatitis MMGs ([Stage III—Pilot Test-ready Draft Phase](#))**
 - The team revised the Generic v2 and Hepatitis MMGs in response to changes suggested by the NBS Team and AgileX.
 - The MMG Development Team delivered updated MMGs to the MVPS Team on 3/20/2015.

- The team also delivered updated test scenarios to the MVPS Team on 3/23/2015 and expects to deliver updated test messages this week.
 - The MMG Development Team expects to post updated versions of the Generic v2 and Hepatitis artifacts to the Draft MMG Web site in April 2015.
 - No guides are in [Stage IV—Final MMG Phase](#) at this time.

Message Validation, Processing, and Provisioning System Updates

- The MVPS Team continues to support the new MMG message restructuring effort.
 - From 3/9/2015 to 3/10/2015, the MVPS Team held clarification meetings with AgileX on the message processing guide (MPG) and processing requirements for the restructured Generic v2, Hepatitis and STD MMGs.
 - The MVPS Team expects to provide updated documents to AgileX by 4/03/2015 based on changes to the MMGs completed by the MMG Development Team on 3/20/2015.
 - The MVPS Team expects to update the Congenital Syphilis requirements document and MPG and provide them to AgileX in April 2015 based on documents expected to be provided by the MMG Development Team in late March 2015.
 - The updated Message Evaluation and Testing Service (METS) tool is expected to be available in June 2015 to support testing of Generic v2, Hepatitis, and STD messages by the jurisdictions.
- The MVPS Team is supporting documentation and clarification of the MVPS system requirements.
 - On 3/10/2015, the team held a clarification session with AgileX on the MVPS Quality Control (QC) Dashboard, Security Roles, and User Interface requirements.
 - On 3/20/2015, the team provided final dashboard and user interface requirements to AgileX.

Technical Assistance Updates

- The team, led by APHL in this effort, completed its conference calls with the initial NMI pilot jurisdictions to reassess their continued interest and readiness to participate in and receive TA between March and June 2015.
 - The team is now reviewing the readiness assessments and determining the jurisdictions that will participate in this phase of NMI TA.
 - When the final pilot sites have been determined and contacted, the team will release that information.
- The team continues to develop tools, resources, and trainings—such as the MMG implementation template, integration broker mappers, and other technical assistance training materials—to assist jurisdictions both before and during technical assistance, which is expected to start in April 2015.
- Reminder about MMG status:
 - MMGs in Stages I, II, and III are considered draft and may be revised until the time they are finalized.
 - Those jurisdictions selected for pilot testing of the test-ready versions (Stage III) of the MMGs should wait until contacted by the NMI TA Team before using the test-ready MMGs, before implementing surveillance information system changes, and before submitting test messages to CDC.

- All other jurisdictions should not plan to submit data to CDC or implement MMG-based updates to their surveillance information systems until the final MMGs (Stage IV) have been posted to the PHIN website.
- For more information about technical assistance:
 - Please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>.
 - For pilot jurisdictions: If you have questions specific to NMI TA, please contact Laura Carlton, APHL, at laura.carlton@aphl.org.
 - For non-pilot jurisdictions: If you have questions or would like to request TA for MMG implementation through the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Cooperative Agreement, please email edx@cdc.gov.

For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.